Literature DB >> 16980641

Some ethical considerations for the "off-label" use of drugs such as Avastin.

D Wong1, G Kyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16980641      PMCID： PMC1857438          DOI： 10.1136/bjo.2006.102426

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  16 in total

1.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

2.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.

Authors:  Philip J Rosenfeld; Anne E Fung; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

3.  Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment?

Authors:  Elias Reichel
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

4.  Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s.

Authors:  A Yoshioka
Journal:  BMJ       Date:  1998-10-31

5.  Why we need observational studies to evaluate the effectiveness of health care.

Authors:  N Black
Journal:  BMJ       Date:  1996-05-11

6.  Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children.

Authors:  S Conroy; I Choonara; P Impicciatore; A Mohn; H Arnell; A Rane; C Knoeppel; H Seyberth; C Pandolfini; M P Raffaelli; F Rocchi; M Bonati; G Jong; M de Hoog; J van den Anker
Journal:  BMJ       Date:  2000-01-08

7.  Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Richard F Spaide; Ketan Laud; Howard F Fine; James M Klancnik; Catherine B Meyerle; Lawrence A Yannuzzi; John Sorenson; Jason Slakter; Yale L Fisher; Michael J Cooney
Journal:  Retina       Date:  2006-04       Impact factor: 4.256

8.  Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.

Authors:  J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan
Journal:  Toxicol Pathol       Date:  1999 Sep-Oct       Impact factor: 1.902

9.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

10.  Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.

Authors:  Irene Barbazetto; Amy Burdan; Neil M Bressler; Susan B Bressler; Laurie Haynes; Anastasios D Kapetanios; Julius Lukas; Karl Olsen; Michael Potter; Al Reaves; Philip Rosenfeld; Andrew P Schachat; H Andrew Strong; Andrea Wenkstern
Journal:  Arch Ophthalmol       Date:  2003-09
View more
  2 in total

Review 1.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Off-label use of medicines: medical research and medical practice.

Authors:  Bakulesh Khamar
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.